Lupin: Lupin launches Posaconazole delayed-release tablets


New Delhi: Drug main on Wednesday stated it has launched Posaconazole delayed-release tablets, used for prevention of invasive aspergillus and candida infections in sufferers at excessive danger as a consequence of low degree of immunity.

Posaconazole delayed-release pill is generic equal of Noxafil delayed-release pill, of Merck Sharp & Dohme Corp.

In a regulatory submitting, Lupin Ltd introduced launch of Posaconazole delayed-release tablets, 100 mg, after its alliance accomplice AET Pharma US Inc. (a part of Tiefenbacher Group) acquired an approval for its abbreviated new drug software (ANDA) from the United States Food and Drug Administration”.

Quoting IQVIA transferring annual complete (MAT) knowledge for December 2020, Lupin stated Posaconazole delayed-release tablets, 100 mg, had estimated annual gross sales of USD 186 million within the US.

Shares of Lupin had been buying and selling 1.71 per cent decrease at Rs 1,077.05 apiece on BSE.

This feed is mechanically printed through